Biomm

Biomm ROCE

The Return on Capital Employed (ROCE) of Biomm (BIOM3.SA) as of Nov 11, 2026 is 1.54 %. In the previous year, Return on Capital Employed (ROCE) was -30.90 % — a change of -104.98% (higher).

ROCE

1.54 %

YoY

-104.98%

Last updated:

In 2025, Biomm's return on capital employed (ROCE) was 1.54 %, a -104.98% increase from the -30.90 % ROCE in the previous year.

The Biomm ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2018
-30.05 BRL
Jan 1, 2019
-30.74 BRL
Jan 1, 2020
-31.01 BRL
Jan 1, 2021
-58.60 BRL
Jan 1, 2022
-53.21 BRL
Jan 1, 2023
-58.91 BRL
Jan 1, 2024
-30.90 BRL
Jan 1, 2025
1.54 BRL
The Biomm ROCE history
YEARROCEYoY
1.54 %-104.98%
-30.90 %-47.54%
-58.91 %+10.72%
-53.21 %-9.19%
-58.60 %+88.93%
-31.01 %+0.87%
-30.74 %+2.31%
-30.05 %-44.19%
-53.85 %-18.41%
-66.00 %+241.57%
-19.32 %+23.56%
-15.64 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Biomm Stock analysis

What does Biomm do? Biomm SA generates revenue through the development and licensing of technology for producing human insulin and other recombinant proteins. The company's patented technology, protected in multiple regions, is used by pharmaceutical firms to manufacture therapeutic proteins for drugs and biopharmaceuticals. Its subsidiaries Biomm International Inc, Biomm Middle East Inc, and Biomm Russia Ltd support global operations. The firm also develops production processes for enzymes used in biomass hydrolysis and bio-fuel manufacturing, targeting industrial applications in renewable energy sectors. The primary buyers of Biomm SA's technology are pharmaceutical companies seeking to produce therapeutic proteins. These firms license the company's patented insulin production methods to integrate into their drug manufacturing processes. The enzyme production technology is sold to companies in the bio-fuel industry, particularly those involved in biomass conversion for renewable energy. Biomm SA's focus on recombinant protein production and bio-fuel applications positions it within the biotechnology and renewable energy markets. The company's business model relies on technology licensing fees and sales of proprietary production processes. Insulin production technology, protected by international patents, forms a significant revenue stream. Enzyme technology for biomass hydrolysis and bio-fuel manufacturing provides additional income from industrial clients. Biomm SA's subsidiaries facilitate international market access, enabling the company to serve global clients across pharmaceutical and renewable energy sectors. Biomm is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Biomm's Return on Capital Employed (ROCE)

Biomm's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Biomm's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Biomm's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Biomm’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Biomm stock

Return on Capital Employed (ROCE) of Biomm is 1.54 % in 2025.

Return on Capital Employed (ROCE) of Biomm changed from -30.90 % to 1.54 %, representing a -104.98% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Biomm since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Biomm with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Biomm

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Biomm